The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
Subscribe To Our Newsletter & Stay Updated
